TrialJournal for immunotherapy of cancer2018

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Yaxiong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.